Tamuzimod is under clinical development by Ventyx Biosciences and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tamuzimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tamuzimod overview

Tamuzimod is under development for the treatment of ulcerative colitis. The drug candidate is administered through oral route. It acts by targeting sphingosine 1-phosphate receptor 1 (S1PR1).

Ventyx Biosciences overview

Ventyx Biosciences is a clinical-stage biotechnology company that discover and develops novel drugs for inflammatory diseases and autoimmune disorders. The company’s pipeline include VTX958, a TYK2 inhibitor for the treatment of various autoimmune diseases; VTX002, S1P1 receptor modulator for the treatment of ulcerative colitis and others. Ventyx Biosciences headquartered in Encinitas, California, the US.

For a complete picture of Tamuzimod’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.